PPARγ Plays an Important Role in Acute Hepatic Ischemia-Reperfusion Injury via AMPK/mTOR Pathway.

IF 3.5 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

PPAR Research Pub Date : 2021-07-03 eCollection Date: 2021-01-01 DOI:10.1155/2021/6626295

Liwei Wu, Qiang Yu, Ping Cheng, Chuanyong Guo

{"title":"PPARγ Plays an Important Role in Acute Hepatic Ischemia-Reperfusion Injury via AMPK/mTOR Pathway.","authors":"Liwei Wu, Qiang Yu, Ping Cheng, Chuanyong Guo","doi":"10.1155/2021/6626295","DOIUrl":null,"url":null,"abstract":"Background: Hepatic ischemia-reperfusion (IR) injury is one of the severe complications associated with liver surgery and leads to liver dysfunction. PPARγ is always linked with various physiologic pathways, and it can alleviate liver damage in IR injury.Aim: In this study, we explored the potential mechanism of PPARγ in the pathogenesis of hepatic IR injury by mice model.Methods: After treated with si-PPARγ or rosiglitazone, mice were subjected to hepatic ischemia-reperfusion. Liver tissue and blood samples were collected to evaluate liver injury and detected relative mRNA and protein expressions.Results: The expression of PPARγ was increased after reperfusion. And the alleviation of PPARγ aggravated the liver damage in IR; at the same time, upregulation of the expression of PPARγ released the liver damage. And these effects of PPARγ in IR were related to the AMPK/mTOR/autophagy signaling pathway.Conclusion: PPARγ plays an important role in hepatic IR injury at least partly via the AMPK/mTOR/autophagy pathway.","PeriodicalId":20439,"journal":{"name":"PPAR Research","volume":" ","pages":"6626295"},"PeriodicalIF":3.5000,"publicationDate":"2021-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275421/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PPAR Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2021/6626295","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Hepatic ischemia-reperfusion (IR) injury is one of the severe complications associated with liver surgery and leads to liver dysfunction. PPARγ is always linked with various physiologic pathways, and it can alleviate liver damage in IR injury.

Aim: In this study, we explored the potential mechanism of PPARγ in the pathogenesis of hepatic IR injury by mice model.

Methods: After treated with si-PPARγ or rosiglitazone, mice were subjected to hepatic ischemia-reperfusion. Liver tissue and blood samples were collected to evaluate liver injury and detected relative mRNA and protein expressions.

Results: The expression of PPARγ was increased after reperfusion. And the alleviation of PPARγ aggravated the liver damage in IR; at the same time, upregulation of the expression of PPARγ released the liver damage. And these effects of PPARγ in IR were related to the AMPK/mTOR/autophagy signaling pathway.

Conclusion: PPARγ plays an important role in hepatic IR injury at least partly via the AMPK/mTOR/autophagy pathway.

Abstract Image

查看原文本刊更多论文

PPARγ通过AMPK/mTOR通路在急性肝缺血再灌注损伤中发挥重要作用

背景:肝缺血再灌注损伤是肝脏手术的严重并发症之一，可导致肝功能障碍。PPARγ与多种生理通路相关，可减轻IR损伤中的肝脏损害。目的:通过小鼠肝IR损伤模型，探讨PPARγ在肝脏IR损伤发生中的潜在机制。方法:用si-PPARγ或罗格列酮治疗小鼠肝缺血再灌注。采集肝组织和血液样本，评估肝损伤情况，检测相对mRNA和蛋白表达。结果:PPARγ在再灌注后表达升高。PPARγ的减轻加重了IR的肝损害;同时，上调PPARγ的表达释放肝损伤。而PPARγ在IR中的作用与AMPK/mTOR/自噬信号通路有关。结论:PPARγ至少通过AMPK/mTOR/自噬途径在肝脏IR损伤中发挥重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

PPAR Research MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

6.20

自引率

3.40%

发文量

审稿时长

12 months

期刊介绍： PPAR Research is a peer-reviewed, Open Access journal that publishes original research and review articles on advances in basic research focusing on mechanisms involved in the activation of peroxisome proliferator-activated receptors (PPARs), as well as their role in the regulation of cellular differentiation, development, energy homeostasis and metabolic function. The journal also welcomes preclinical and clinical trials of drugs that can modulate PPAR activity, with a view to treating chronic diseases and disorders such as dyslipidemia, diabetes, adipocyte differentiation, inflammation, cancer, lung diseases, neurodegenerative disorders, and obesity.